Sage Therapeutics (SAGE) announced that Dr. Laura Gault, Chief Medical Officer, has decided to pursue a new opportunity and will depart the Company, effective March 21, 2025. Dr. Gault joined Sage Therapeutics in November 2022 and has led the Company’s product pipeline through all stages of development. Mike Quirk, Chief Scientific Officer, will assume key responsibilities, including strategic guidance for clinical development programs, on an interim basis.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- SAGE Therapeutics: Hold Rating Amid Gradual Growth Prospects and Market Challenges
- Sage Therapeutics price target established at JPMorgan
- SAGE Therapeutics Faces Legal Challenges: Potential Impact on Financial Stability and Growth
- Hold Rating for SAGE Therapeutics: Inventory Challenges and Strategic Prospects
- SAGE Therapeutics’ Earnings Call: ZURZUVAE’s Success Amid Challenges